LBLaura Hinkle Bachmann

Laura Hinkle Bachmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Hinkle Bachmann has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron Karacuschansky

    George Washington University School of Public Health, Washington, District of Columbia

    1 shared publication
  • Alexis Osei

    George Washington University School of Public Health, Washington, District of Columbia

    1 shared publication
  • Arlene C Seña

    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

    1 shared publication
  • Aziz Mert Ipekci

    Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

    1 shared publication
  • Candice J McNeil

    Department of Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA

    1 shared publication
  • Carolyn Deal

    Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Rockville, Maryland , USA

    1 shared publication

Latest Publications

  • Open Access

    Summary of the Centers for Disease Control and Prevention/National Institute of Allergy and Infectious Diseases Joint Workshop on Genital Herpes: 3–4 November 2022

    by Kristie L Connolly, Laura Bachmann, Thomas Hiltke, Ellen N Kersh, Lori M Newman, Lydia Wilson, Leandro Mena, Carolyn Deal

    Genital herpes is caused by infection with herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and currently has no cure. The disease is the second-most common sexually transmitted infection in the United States, with an estimated 18.6 million prevalent genital infections caused by HSV-2 alone. Genital herpes diagnostics and treatments are not optimal, and no vaccine is currently available. The Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases convened a workshop entitled “CDC/NIAID Joint Workshop on Genital Herpes.” This report summarizes 8 sessions on the epidemiology of genital herpes, neonatal HSV, HSV diagnostics, vaccines, treatments, cures, prevention, and patient advocacy perspective intended to identify opportunities in herpes research and foster the development of strategies to diagnose, treat, cure, and prevent genital herpes.


  • Top Cited Papers

    Syphilis Complicating Pregnancy and Congenital Syphilis

    by Irene A Stafford, Kimberly A Workowski, Laura H Bachmann


  • Congenital Syphilis in the Medicaid Program: Assessing Challenges and Opportunities Through the Experiences of Seven Southern States

    by Naomi Seiler, William S. Pearson, Laura H. Bachmann, Claire Heyison, Paige Organick-Lee, Aaron Karacuschansky, Gregory Dwyer, Alexis Osei, Helen Stoll, Katie Horton


  • Open Access

    Mpox virus and transmission through sexual contact: Defining the research agenda

    by Nicola Low, Laura H. Bachmann, Dimie Ogoina, Robert McDonald, Aziz Mert Ipekci, Laura A. S. Quilter, Muge Cevik

    In a Policy Forum piece, Dr. Nicola Low and colleagues define the research agenda for Mpox virus and transmission through sexual contact.


  • Field Services Facilitated Treatment and Prevention: Challenges and Opportunities

    by Laura Hinkle Bachmann, Roxanne P. Kerani

    Assisted partner services (APS) is a longstanding public health strategy to reduce transmission of STI and HIV in the U.S. However, with rapidly increasing rates of STI, innovations to APS are needed to allow health departments to conserve limited public health resources while improving the effectiveness of APS. Disease Intervention Specialists (DIS), public health staff who conduct APS, have a wealth of experience in identifying, locating, and interviewing index patients and their sexual partners, but are currently limited in the services that they are able to provide in the field. While several state and local health departments are working to expand the role of DIS to incorporate less traditional APS activities, such programs are uncommon. We discuss several services that DIS could conceivably provide in the field, such as STI testing, treatment, and vaccination, and identify critical issues to be addressed in order to implement these changes in DIS activities on a larger scale. Broadening the scope of DIS activities may result in multiple benefits to health departments, including more effectively delivering STI testing and treatment to hard to reach populations, imparting more responsibility to DIS, thereby potentially increasing job satisfaction, and building a workforce that is better prepared for public health crises. Effective approaches to address variable state level regulations governing DIS scope of practice are needed.


  • Open Access

    Prevalence of Mycoplasma genitalium Infection, Antimicrobial Resistance Mutations, and Symptom Resolution Following Treatment of Urethritis

    by Laura H Bachmann, Robert D Kirkcaldy, William M Geisler, Harold C Wiesenfeld, Lisa E Manhart, Stephanie N Taylor, Arlene C Seña, Candice J McNeil, Lori Newman, Noelle Myler, et al.

    Antimicrobial resistance in Mycoplasma genitalium (MG), a cause of urethritis, is a growing concern. Yet little is known about the geographic distribution of MG resistance in the United States or about its associated clinical outcomes. We evaluated the frequency of MG among men with urethritis, resistance mutations, and posttreatment symptom persistence. We enrolled men presenting with urethritis symptoms to 6 US sexually transmitted disease (STD) clinics during June 2017–July 2018; men with urethritis were eligible for follow-up contact and, if they had persistent symptoms or MG, a chart review. Urethral specimens were tested for MG and other bacterial STDs. Mutations in 23S ribosomal ribonucleic acid (rRNA) loci (macrolide resistance–associated mutations [MRMs]) and in parC and gyrA (quinolone-associated mutations) were detected by targeted amplification/Sanger sequencing. Among 914 evaluable participants, 28.7% (95% confidence interval [CI], 23.8–33.6) had MG. Men with MG were more often Black (79.8% vs 66%, respectively), parC mutations, and 0% had gyrA mutations. Among participants treated with azithromycin-based therapy at enrollment and who completed the follow-up survey, persistent symptoms were reported by 25.8% of MG-positive/MRM-positive men, 13% of MG-positive/MRM-negative men, and 17.2% of MG-negative men. MG infection was common among men with urethritis; the MRM prevalence was high among men with MG. Persistent symptoms following treatment were frequent among men both with and without MG.


  • Faculty Opinions recommendation of One lesion, one virus: individual components of high-grade anal intraepithelial neoplasia in HIV-positive men contain a single HPV type.

    by Laura Bachmann

    The incidence of anal cancer in HIV-positive men who have sex with men continues to increase with rates exceeding the rate of cervical cancer before the advent of the screening era. Similar to cervical cancer, anal cancer appears to arise from high-grade anal intraepithelial neoplasia (HGAIN) and has been strongly associated with the presence of oncogenic human papillomavirus (HPV). Optimal screening and management strategies for HGAIN remain undefined and are the subjects of ongoing investigation. In the meantime, building upon the knowledge base related to the natural history of HPV, HGAIN and anal cancer will contribute to improved future screening and treatment strategies. This study presents novel data made possible through the combined use of laser-capture microdissection (LCM) and type-specific PCR to detect the lesion-specific HPV genotype in anal biopsy specimens obtained from suspect lesions. The current study represents a substudy of a larger trial on AIN treatment at an HIV clinic in Amsterdam. Patients were screened by high-resolution anoscopy (HRA) with biopsy specimens obtained from suspect lesions. Twenty-one patients with histologically proven high-grade neoplasia were included, representing a total of 31 HGAIN lesions. The majority of patients had anal swab specimens collected for HPV analysis within 4 weeks of biopsy. DNA was isolated from whole-tissue sections of the 31 HGAIN lesions. The SPF10 PCR/LiPA 25 HPV genotyping system was used for DNA analysis and in tissue sections with multiple HPV types, PCR was repeated in regions of AIN sampled by LCM and compared with HPV types in anal swabs. The median age of men was 48 years, median HIV infection duration 11 years and median CD4 480 with the majority of men (95%) on antiretroviral therapy. A single HPV type was detected in 15 (48%) of the lesions and multiple types in 16 (52%) with a median of two HPV types per whole-tissue section (the predominant type was HPV 16 -- found in around half of the specimens; HPV 18 was found in 13% of the lesions). Interestingly, when multiple HPV types were found in whole tissue specimens, a single HPV type was found in each component of the HGAIN lesion in 94% of the cases. The two lesions that contained more than one HPV type within a single HGAIN lesion appeared to represent 'collision lesions' involving two separate single genotype HPV infections. Of note, 8/15 (53%) of the anal swab specimens did not contain all of the lesional HPV types found in whole tissue or LCM specimens -- bringing into question the usefulness of anal swabs for detecting the HPV virus causing HGAIN. I found this study to be both elegant in design and fascinating. While it confirms findings described earlier in the setting of cervical intraepithelial neoplasia, it is novel in the application of the methods to anal disease, especially given the prevalence of HPV (and multiple HPV strains) documented to date in anal swabs obtained from this population. So despite the 'milieu' of HPV present in the swabs (median number of four with a range of 1-13 genotypes), utilizing LCM technology and advanced molecular detection methods allowed the investigators to hone down on one virus associated with one high-grade lesion in the vast majority of cases. It is also important to point out that a significant number of the HGAIN-associated HPV strains are not currently covered in the 4-valent HPV vaccine -- though the recently approved 9-valent vaccine will pick up a significant number of additional strains documented in this study.

  • Open Access

    New Syphilis Cases and Concurrent STI Screening in a Southeastern U.S. HIV Clinic: A Call to Action

    by Cynthia W. Baffi, Inmaculada Aban, James H. Willig, Mayank Agrawal, Michael J. Mugavero, Laura H. Bachmann

    Syphilis outbreaks in the United States have been reported since 2000 with highest rates in the South and many cases among HIV-infected individuals. We evaluated incident syphilis cases and concurrent gonorrhea and chlamydia screening at a southern HIV clinic. A retrospective cohort study included HIV-infected patients with at least one reactive plasma reagin (test for serum reagin antibodies to cardiolipin-cholesterol-lecithin antigen) and primary care visit from July 2004 to June 2007. Primary, secondary, and early latent syphilis cases were identified as incident syphilis and evaluation for gonorrhea and chlamydia within 1 month were described. Logistic regression was performed to determine factors associated with incident syphilis. Among 1544 patients, 40 incident syphilis cases were identified (5 primary, 29 secondary, and 6 early latent). The majority of patients were not virologically suppressed and only 25% had gonorrhea and chlamydia testing. In adjusted analyses, younger age (0.57 per 10 years, 95% confidence interval [CI] 0.41–0.80) and minority race (2.26, 95% CI 1.12–4.59) were associated with incident syphilis. Among 40 incident syphilis cases, only 1 in 4 were further tested for gonorrhea and chlamydia. These low rates are concerning as concurrent sexually transmitted infections (STIs) increase risk for HIV transmission. HIV care provider education with emphasis on STI testing in the setting of incident syphilis is key in prevention.


  • Yes, the sexual history IS important

    by Patricia R. Jennings, Laura Bachmann